NasdaqCM:BLFSLife Sciences
A Look At BioLife Solutions (BLFS) Valuation After New Qkine Cell And Gene Therapy Partnership
BioLife Solutions (BLFS) has drawn investor attention after announcing a multi year supply agreement with Qkine Limited, which grants it exclusive worldwide distribution rights to select cytokine and growth factor products for cell and gene therapy applications.
See our latest analysis for BioLife Solutions.
The Qkine agreement arrives after a weak patch for the stock, with a 30 day share price return of 8.48% and a 1 year total shareholder return decline of 19.95%, suggesting recent...